Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

1.495 +0.095 (+6.79%)
Streaming Delayed Price Updated: 2:48 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
News headline image
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform. 
Via Benzinga
News headline image
Update: SciSparc To Spin Off Pharmaceutical Activities Into New Subsidiary ↗
The jury is out on how well SciSparc will do in executing its restructuring plan, but the company has no other choice. 
Via Talk Markets
News headline image
SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression ↗
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
News headline image
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
News headline image
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
News headline image
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 93 stocks made new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 95 stocks hit new 52-week lows. 
Via Benzinga
News headline image
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Welcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Completes Production Of Its Dronabinol-Based Drug Candidate For Its Clinical Trial On Tourette Syndrome ↗
SciSparc Ltd. (NASDAQ: SPRC) has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome. 
Via Benzinga
News headline image
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
SciSparc's CBD-Based Drug One Step Closer To Clinical Trial On Children With Autism Spectrum Disorder ↗
SciSparc Ltd. (NASDAQ: SPRC) has signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE:TKUN), to supply... 
Via Benzinga
News headline image
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
News headline image
Jeffs' Brands To Acquire A 49% Interest In A Company That Owns A Top Seller Brand On Amazon For $2.5M ↗
Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, has entered into a definitive agreement with SciSparc Ltd. 
Via Benzinga
News headline image
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
From Jeffs' Brands Ltd
Via GlobeNewswire
News headline image
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
News headline image
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
News headline image
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
News headline image
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket ↗
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
News headline image
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. 
Via Benzinga
News headline image
Why SciSparc Shares Are Moving During Friday's Session ↗
SciSparc Ltd (NASDAQ: SPRC) shares are trading higher by 8.08% to $0.98 Friday morning, though off the session high of $1.33, after the company announced its MitoCareX Bio joint venture achieved... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.